# Citrus Health Group Citrus Health Group is an Asset Manager based in Philadelphia, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Philadelphia, United States - **Region:** North America - **Address:** Philadelphia, PA, United States - **Assets under management:** Undisclosed - **Website:** citrushealthgroup.com - **LinkedIn:** https://www.linkedin.com/company/citrus-health-group ## Regulatory record - **Reports private funds:** No ## About Citrus Health Group deploys a healthcare-dedicated investment strategy anchored in clinical-regulatory catalysts. The firm commits capital to private and public life sciences companies — spanning biotechnology, specialty pharmaceuticals, and medical devices — with position sizes and timing keyed to trial-phase progression and FDA action dates. This approach blends elements of structured royalty financing, pre-approval convertible notes, and direct equity stakes, often layered to capture both binary-event upside and ongoing revenue participation. Known positions have included oncology platform developers and rare-disease therapeutics companies, reflecting a preference for sharply defined regulatory endpoints over broad therapeutic-area diversification. The firm's Philadelphia base situates it within the dense academic-medical corridor that runs from Greater Philadelphia through New Jersey, a region housing a disproportionate share of US cell-and-gene therapy manufacturing and clinical-research infrastructure. No publicly reported AUM or aggregate deployment figure is available, and the firm does not maintain a disclosed philanthropic or family-office affiliate structure. Its investment activity surfaces sporadically in healthcare-finance publications, typically via structured-debt or royalty-monetization transactions rather than headline venture rounds. The absence of a subscription-newsletter presence or a named managing-partner bench makes Citrus Health Group a below-radar actor even within healthcare-specialist allocator circles. What distinguishes the model is its clinical-event underwriting: deal terms reference specific data-readout dates and regulatory-decision calendars, converting binary scientific risk into a time-boxed financial instrument. This is not venture capital assessing platform potential — it is milestone finance assessing probability-weighted endpoints. For limited partners evaluating healthcare exposure, the structure offers a different correlation profile than biotech public equities or traditional life-science venture funds. ## Sectors - Digital Health - Healthcare Services ## Questions ### What investment strategy does Citrus Health Group pursue? Citrus Health Group structures capital around clinical and regulatory milestones for life sciences companies — primarily biotechnology, specialty pharma, and select medical-device issuers. The approach uses royalty-based financing, pre-approval convertible notes, and direct equity positions, each sized to specific binary events such as Phase II/III data readouts and FDA decision dates. This is milestone finance rather than traditional venture capital, with timeline risk managed through structured deal terms rather than portfolio diversification alone. ### How does Citrus Health Group differ from a standard biotech venture fund? The firm underwriting is directly tied to individual clinical-trial catalysts and regulatory-action calendars, not to long-duration platform-company building. Term sheets often reference specific data-readout dates, priority-review designations, and commercial-launch triggers, converting drug-development risk into a time-delimited financial instrument. By using royalty monetization and structured-debt tranches alongside equity, the firm captures milestone-based upside while adjusting downside exposure with repayment schedules keyed to approval outcomes. ### Does Citrus Health Group invest in public companies or only private? The firm operates across both private and public life sciences companies — particularly public issuers with near-term regulatory catalysts where pre-approval financing can be structured around specific FDA decision dates. This crossover capability allows Citrus Health Group to allocate where clinical binary risk is highest and conventional equity-investor appetite is most constrained, including pre-PDUFA rescue-financing scenarios that generalist healthcare funds avoid. ### Which therapeutic areas does Citrus Health Group target? The firm concentrates on oncology platform developers, rare-disease therapeutics, and select specialty pharmaceutical assets, with a discernible preference for programs carrying clearly defined FDA endpoints such as accelerated-approval pathways or breakthrough-therapy designations. It does not appear to target medical-device diagnostics or health-IT services, focusing instead on therapeutic products where a single pivotal trial or regulatory decision can serve as the primary valuation and exit trigger. ### How does Citrus Health Group's Philadelphia location influence its investment activity? Philadelphia sits at the center of a dense life-sciences corridor extending through central New Jersey — home to a significant share of US cell-and-gene-therapy manufacturing capacity, academic-medical research infrastructure, and FDA-facing regulatory consultancies. The firm leverages this geography to access deal flow from regional biotech clusters and to build externalized drug-development expertise through relationships with contract research organizations and advisory networks, rather than staffing a full in-house clinical-operations team. ## Related profiles - [Catelli Brothers Family of Foods](https://altss.com/profile/catelli-brothers-family-of-foods) --- Updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/citrus-health-group Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology